Literature DB >> 15055508

Survey of cannabis use in patients with amyotrophic lateral sclerosis.

Dagmar Amtmann1, Patrick Weydt, Kurt L Johnson, Mark P Jensen, Gregory T Carter.   

Abstract

Cannabis (marijuana) has been proposed as treatment for a widening spectrum of medical conditions and has many properties that may be applicable to the management of amyotrophic lateral sclerosis (ALS). This study is the first, anonymous survey of persons with ALS regarding the use of cannabis. There were 131 respondents, 13 of whom reported using cannabis in the last 12 months. Although the small number of people with ALS that reported using cannabis limits the interpretation of the survey findings, the results indicate that cannabis may be moderately effective at reducing symptoms of appetite loss, depression, pain, spasticity, and drooling. Cannabis was reported ineffective in reducing difficulties with speech and swallowing, and sexual dysfunction. The longest relief was reported for depression (approximately two to three hours).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15055508     DOI: 10.1177/104990910402100206

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  21 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

2.  Dosing medical marijuana: rational guidelines on trial in Washington State.

Authors:  Sunil K Aggarwal; Muraco Kyashna-Tocha; Gregory T Carter
Journal:  MedGenMed       Date:  2007-09-11

Review 3.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

Review 4.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

Review 5.  Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.

Authors:  Johannes Brettschneider; Jerome Kurent; Albert Ludolph
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

6.  Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.

Authors:  G Gobbi; F R Bambico; R Mangieri; M Bortolato; P Campolongo; M Solinas; T Cassano; M G Morgese; G Debonnel; A Duranti; A Tontini; G Tarzia; M Mor; V Trezza; S R Goldberg; V Cuomo; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

Review 7.  Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Authors:  Javier Fernández-Ruiz; María A Moro; José Martínez-Orgado
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 8.  Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.

Authors:  Chafic Y Karam; Sabrina Paganoni; Nanette Joyce; Gregory T Carter; Richard Bedlack
Journal:  Am J Hosp Palliat Care       Date:  2014-09-08       Impact factor: 2.500

9.  Depression and quality of life issues in patients with amyotrophic lateral sclerosis.

Authors:  Shannon F Stromberg; David B Weiss
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

Review 10.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.